Overview

• Novo Nordisk announced it will limit supplies of starter doses for new patients of its popular weight-loss drug Wegovy in the U.S. to ensure adequate supply for existing patients.
• The high demand for Wegovy has outpaced Novo Nordisk's manufacturing capacity, leading to nationwide shortages of the drug.
• Wegovy belongs to a promising new class of weight-loss drugs known as GLP-1 agonists that some analysts predict could become a $100 billion market.
• Novo Nordisk is working to increase manufacturing capacity but shortages are expected to continue into September.
• The company recommended patients currently on Wegovy contact pharmacies ahead of refills and try multiple locations to fill prescriptions.